The effect of CagA status on response to Helicobacter pylori eradication therapy in Western Turkey

Brazilian Journal of Medical and Biological Research

Volumn 34, Issue 11, 2001, Pages 1435-1439

  Saruc M ^a,b   Goksel, G ^a   Ozkaya, S ^a   Guclu, F ^a   Ozbakkaloglu, B ^a   Yuceyar, H ^a  

^a CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Altin Sok Kirazlik ince   (Turkey)

Author keywords

CagA; Cytotoxin associated gene A; Eradication; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CAGA PROTEIN; CLARITHROMYCIN; GASTRIN; LANSOPRAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; CHRONIC GASTRITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GASTRIN BLOOD LEVEL; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN DETERMINATION; RISK FACTOR; STATISTICAL ANALYSIS; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH FUNDUS; STOMACH MUCOSA; STRAIN DIFFERENCE; TREATMENT FAILURE; TURKEY (REPUBLIC);

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI;

EID: 0035673416     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2001001100010     Document Type: Article

References (19)

1. Helicobacter pylori and peptic ulcer disease
2. Therapy of Helicobacter pylori infection
3. Double blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer
4. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan
5. Helicobacter pylori expressing CagA and VacA delays the healing of ischemia-reperfusion injury, a new model of studying Hp-pathogenesis
6. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I study
7. Immune and inflammatory response to Helicobacter pylori infection
8. Gastric mucosal inflammatory response to Helicobacter pylori
9. Eradication treatment of Helicobacter pylori infection in CagA positive and CagA negative patients
10. CAg negative status: A risk factor for failure of Helicobacter pylori triple therapies in non-ulcer dyspepsia
11. Effect of Helicobacter pylori eradication on gastritis in relation to CagA: A prospective 1-year follow-up study
12. Importance of Helicobacter pylori CagA and VacA status for the efficacy of antibiotic treatment
13. CagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia
14. Immunologic aspects of Helicobacter pylori infection and malignant transformation of B cells
15. Increased mucosal inflammatory cytokines in children with Helicobacter pylori-associated gastritis
16. Cytokine-mediated activation of vascular endothelium
17. Plasma beta-thromboglobulin in severe infections
18. Extradigestive diseases and Helicobacter pylori infection
19. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease